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Background: Glioblastoma multiforme (GBM), the most common and most aggressive type of primary adult brain
tumour, responds poorly to conventional treatment. Temozolomide (TMZ) chemotherapy remains the most commonly
used treatment, despite a large proportion of tumours displaying TMZ resistance. 60% of GBM tumours have
unmethylated MGMT promoter regions, resulting in an overexpression of the DNA repair protein O6-methylguanine-DNA
methyltransferase (MGMT), which is responsible for tumour resistance to TMZ chemotherapy. Tumours also often exhibit
hyperactive PI3-kinase/mTOR signalling, which enables them to resynthesise proteins quickly. Since MGMT is a suicide
protein that is degraded upon binding to and repairing TMZ-induced O6-methylguanine adducts, it has been
hypothesized that inhibition of translation via the mTOR signalling pathway could generate a tumour-specific
reduction in MGMT protein and increase TMZ sensitivity.
Methods: MGMT was monitored at the post-transcriptional, translational and protein levels, to determine what
effect mTOR inhibition was having on MGMT protein expression in vitro.
Results: We show that inhibiting mTOR signalling is indeed associated with acute inhibition of protein synthesis.
Western blots show that despite this, relative to loading control proteins, steady state levels of MGMT protein
increased and MGMT mRNA was retained in heavy polysomes. Whilst TMZ treatment resulted in maintained MGMT
protein levels, concomitant treatment of T98G cells with TMZ and KU0063794 resulted in increased MGMT protein
levels without changes in total mRNA levels.
Conclusions: These in vitro data suggest that, counterintuitively, mTOR inhibition may not be a useful adjunct to
TMZ therapy and that more investigation is needed before applying mTOR inhibitors in a clinical setting.
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Glioblastoma (GBM), a WHO grade IV astrocytoma, is
the most common [1] and most aggressive type of primary
brain tumour. Current treatment consists of tumour re-
section (where possible), followed by ionising radiotherapy
combined with concomitant and adjuvant temozolomide
(TMZ) chemotherapy [2]. TMZ is a methylating agent
that creates lesions in DNA, the most cytotoxic of which
is O6-methylguanine [3]. This multimodal treatment regi-
men is rigorous, yet prognosis remains poor and although
TMZ chemotherapy improves survival in a subset of pa-
tients, 75% die within 2 years and the vast majority of pa-
tients experience disease recurrence [4].* Correspondence: s.smalley@bsms.ac.uk
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unless otherwise stated.O6-methylguanine-DNA methyltransferase (MGMT) is
a DNA repair protein, which removes O6-methylguanine
adducts from damaged DNA [5]. This reaction is irrevers-
ible and once bound to the alkyl group MGMT is ubiquiti-
nated and destroyed by the proteasome [6]. The cytotoxic
effect of TMZ chemotherapy is therefore influenced by
the ability of tumour cells to re-synthesise MGMT and
maintain steady state levels of the protein. Previous work
has shown that MGMT promoter methylation resulting in
gene silencing and resultant low levels of MGMT protein,
increases sensitivity to TMZ and is associated with im-
proved patient survival. Unfortunately direct inhibition of
MGMT using small molecule inhibitors such as lomegua-
trib has not been successful as a clinical application be-
cause it also increases haematological toxicity [2,7,8].
However, downregulation of MGMT remains an attractivel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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unmethylated MGMT promoters if it could be achieved in
a tumour specific manner.
Common mutations in GBM cells include genetic
changes that result in a loss of PTEN function and EGFR
amplification [9], both of which can generate hyperactive
phosphoinositide 3-kinase (PI3K)/mTOR signalling. mTOR
is a serine/threonine kinase that belongs to the PI3K-
related kinase family and interacts with proteins to form
two distinct complexes in mammals, mTORC1 and
mTORC2 [10]. mTORC1, when active, regulates protein
translation through the phosphorylation of 4EBP1. Phos-
phorylation of 4E-BP1 prevents it binding to eIF4E, which
enables eIF4E to participate in the formation of the eIF4F
complex on the m7 GTP cap structure of mRNA and me-
diate small ribosomal subunit binding and subsequent
protein translation [11]. The hyperactivity of this pathway
therefore results in increased protein synthesis, promoting
cell growth and proliferation.
Because of this there has been interest in the use of
mTOR inhibitors in combination with radiation and TMZ
in the treatment of GBM. The rationale for combining
mTOR inhibitors with TMZ treatment is based on the rea-
soning that the lesions in DNA caused by TMZ will result
in a depletion of cellular MGMT protein levels. When
coupled with mTOR inhibition, not only would there be a
decrease in MGMT levels, but the tumour cell would be
compromised in its ability to synthesise new protein, thus
sensitising the cells to further TMZ treatment. In addition
to this, tumour cells should be specifically targeted with this
course of treatment, due to the tumour cells oncogenic ad-
diction to the PI3K/mTOR signalling pathway. This would
avoid the current drawbacks faced during direct inhibition
of MGMT, as it would avoid MGMT depletion in healthy
cells, and therefore avoid undesirable cytotoxicity.
In this work, we have used Western blotting to examine
the effect of inhibiting mTORC1/2 signalling on steady
state MGMT protein levels in T98G GBM cells, a cell line
which exhibits relatively high MGMT expression com-
pared to other glioblastoma cell lines [12,13]. KU0063794
is a specific mTORC1 and mTORC2 inhibitor that does
not display significant activity against similar kinases such
as PI3K, ERK1/2, or p38MAPK [14].
The findings described in this paper are of both bio-
chemical and potential clinical interest. The research high-
lights how important it is to identify how DNA repair
proteins are translated and maintained as proteins, which is
an important consideration, especially when manipulating
them for clinical benefit.
Materials and methods
Cell culture
T98G (ECACC) cells were cultured to confluency in
minimum essential medium (MEM) supplemented with5% non-essential amino acids (Invitrogen, UK), 10% foetal
calf serum (Biosera, UK) and 5% GlutaMax (Invitrogen,
UK). U87 (ECACC) cells were cultured in the same manner
but with Hyclone foetal calf serum.
Concentrations of drug treatments
Cells were treated with the following concentrations of
drugs: 10 μM KU0063794, 10 μM TMZ and 10 μM
emetine.
Preparation of cell extracts
Following treatment, cells were isolated in a cooled micro-
fuge and washed briefly with 0.5 ml ice-cold PBS. Pellets
were resuspended in 100 μl ice-cold lysis buffer (20 mM
MOPS-KOH, pH 7.2, 20 mM sodium fluoride, 1 μM
microcystin LR, 75 mM KCl, 2 mM MgCl2, 2 mM benza-
midine, 2 mM Na3VO4, complete protease inhibitor mix
(−EDTA (Roche, UK), 0.1% (v/v) SDS), with the addition
of 0.5% (v/v) Igepal and 0.5% (w/v) deoxycholate (DOC)
with vortexing. Cell debris was removed by centrifugation
in a microfuge for 5 min at 4°C and the resultant superna-
tants recovered.Western blotting
Samples containing equal amounts of protein (10 μg) were
resolved by polyacrylamide gel electrophoresis (SDS-
PAGE) and processed as described previously [15,16].
Briefly, membranes were blocked using TBS-Tween con-
taining 3% (w/v) BSA for 1 hour and incubated with anti-
sera diluted in the same overnight at 4°C. Following
washing in TBS-Tween, membranes were incubated with
horseradish peroxidase-conjugated secondary antibody and
signals developed using ECL reagent. The antiserum used
were raised against: eIF4A, phospho-eIF4E, eIF4G, eIF4E
[15,16]; MGMT, phospho-eIF2α, (Abcam, UK); 4E-BP1,
phospho-4E-BP S65, phospho-4E-BP1 T70, phospho-
p70 S6K T389, phospho- ERK1/2, phospho-p38 MAPK,
phospho-rpS6 S240/44, phospho-Akt T308, p21cip1 (Cell
Signaling, UK).[35S]-methionine labelling of cellular protein
One hour prior to harvesting, T98G cells were pulse-
labelled with [35S]-methionine (MP Biomedicals, UK;
10 μCi/ml) and cell extracts prepared as above and 5 μl of
extract was spotted onto Whatman filter papers. Filters
were transferred to 10% (v/v) trichloroacetic acid (TCA)
containing 5 mM unlabelled methionine for 15 minutes
then boiled in 5% (v/v) TCA. Once cooled, the filters were
washed in ethanol, then acetone, dried and subjected to li-
quid scintillation counting. Protein synthesis, expressed as
cpm/ μg protein, is shown as a % of the rate obtained in
cells incubated in the absence of drugs.
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Cells were cultured in a 96 well plate in 100 μl of complete
medium. Following incubation with drugs, 20 μl of MTS/
PMS solution (Promega, UK) was added, and left for
2 hours at 37°C. The colour reaction, reflecting metabolic
activity was quantified by measuring absorbance at A490
using the control wells for comparison. All assays were
carried out in triplicate.
Flow cytommetry
Following incubation of cells as described in the figure leg-
ends, cells were washed with warm PBS then trypsinised
and removed from culture dishes. Cells were washed in
PBS and fixed in 70% ethanol/30% PBS at 4°C overnight.
Immediately before analysis, the cells were washed in PBS
and re-suspended in 500 μl PBS containing 0.1 mg/ml
RNase A (Sigma, UK) and 30 μg/ml propidium iodide
(Invitrogen, UK) and analysed by a FACSCanto™ flow
cytometer (BD Biosciences) using BD FACSDiva™ soft-
ware. Data shown are representative of those obtained in
at least three separate experiments.
Quantitative RT-PCR
RNA was extracted from cell extracts using an RNA easy
mini-kit (Qiagen, UK) as per manufacturer’s instructions.
RNA concentration was then quantified using a Nanodrop
and 1 μg of RNA was used for cDNA synthesis using the
Promega ImpromII kit. The SYBR real-time PCR system
(Kapa Biosystems, UK) was used to quantify transcript
abundance for genes of interest and18S mRNA was used as
a control. Template equivalent to 5 ng of RNA in cDNA li-
brary per reaction was added to each 20 μl reaction with a
final primer concentration of 200 nM per reaction. Cross-
ing thresholds were determined using MxPro software
(Agilent), and fold-difference in RNA quantity was calcu-
lated using the relative quantification method (2-ΔΔct).
Immunofluorescence
Cells were plated on glass coverslips 8 hours before treat-
ment. Cells were then fixed with 4% (w/v) paraformaldehyde
for 20 minutes at room temperature and permeabilised for
5 minutes in 0.1% Triton X-100/PBS. Cells were blocked for
20 minutes with 5% (w/v) gelatin/PBS in a humidified
chamber. Cells were incubated with anti-MGMT (Abcam,
UK) for 1 hour at room temperature also in a humidified
chamber. Alexa Fluor 555-conjugated anti-rabbit secondary
antibody was added for 1 hour at room temperature. Alexa
Fluor 488 phalloidin was also used in the secondary anti-
body incubation. Following further extensive washing,
nuclei were stained with DAPI (4’, 6-diamidino-2-phe-
nylindole) for 5 minutes. After a further two washes,
coverslips were mounted on microscope slides with
Mowiol mounting solution (0.2 M Tris/HCl (pH 8.5),
33% (w/v) glycerol, 13% (w/v) Mowiol and 2.5% (w/v)DABCO (1, 4-diazobicyol [2]-octane)) and sealed with
clear nail polish. Images were collected on a Zeiss Axio-
vert LSM510 scanning confocal microscope using a × 100
objective. Single stain, bleed-though controls and antibody
cross-reaction controls were prepared for each sample
(results not shown).
m7GTP-Sepharose affinity chromatography
To isolate eIF4E and associated proteins [15,16] cells were
lysed as described and aliquots containing 100 μg were in-
cubated with 30 μl (50% v/v in 1 mg/ml cytochrome c)
m7GTP-Sepharose resin for 15 mins on ice, with mixing.
The resin was washed twice in 200 μl buffer (20 mM
MOPS/KOH pH 7.2, 75 mM KCl, 2 mM benzamidine,
7 mM 2-mercaptoethanol, 2 mM MgCl2, 0.1 mM GTP,
complete protease inhibitor mix (−EDTA), 25 mM NaF).
To visualise eIF4E and associated proteins, the resin was
washed twice with 200 μl buffer then eluted in SDS-PAGE
sample buffer containing 10% w/v β-mercaptoethanol prior
to Western blotting.
Polysome profiles
Cells were treated with 100 μg/ml of cycloheximide
(Sigma, UK) for 3 mins before harvesting. The cells were
washed twice in PBS containing 100 μg/ml cycloheximide
and lysed in hypertonic lysis buffer (10 mM Tris/HCl
pH7.5, 10 mM KCl, 15 mM MgCl2, 1%(v/v) Igepal, 0.5%
(v/v) DOC, 40 mM β-glycerophosphate, complete prote-
ase inhibitor mix (−EDTA), 2 mM DTT, 100 μg/ml cyclo-
heximide, 10 U/ml RNase inhibitor) for 15 minutes on
ice and homogenised every 5 mins. The cell lysate was
centrifuged at 14,000 rpm for 3 mins and the super-
natant was separated on a 11.2 ml sucrose gradient (10-
60% (w/v) in hypertonic lysis buffer) for 130 mins at 38,
000 rpm using a Beckman SW40 rotor and fractionated
using an ISCO, monitoring A260 nm through a flow cell.
For analysis of GAPDH and MGMT mRNA, the mRNA
from pooled fractions was extracted and quantitative
RT-PCR was used to determine mRNA distribution
across each fraction.
Results
TMZ does not affect steady state levels of MGMT protein
or protein synthesis in T98G cells
TMZ treatment causes damage to DNA, creating O6-
methylguanine lesions, which are repaired by MGMT
[17,18]. As TMZ is the standard treatment for patients
with GBM [2], we investigated its effect on mTORC1
signalling and MGMT levels in the T98G GBM cell
line. Cells were incubated with TMZ over a 72 hour
time period. This time point was chosen as treatment
regimens are routinely administered between 1 and
5 days each month to patients, due to a low tolerance
of the drug [4,19]. SDS-PAGE and Western blotting
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used as a protein loading control, TMZ does not result
in a significant change in MGMT protein levels be-
tween 24 and 72 hours of incubation (Figure 1A).
Quantification of these data from three separate exper-
iments (using eIF4A as a loading control; error bars are
SE) showed that although there was some experimental
variability between time-courses, there was no significant
difference in MGMT protein levels following treatment of
cells with TMZ (Figure 1B). Similar results were obtained
when alpha tubulin was used as a loading control to nor-
malise levels of MGMT protein between experiments (see
below). Neither FACS analysis (Additional file 1: Figure
S1) nor mitochondrial toxicity assays (Additional file 1:
Figure S2) showed any effect of TMZ on cell death under
these assay conditions. 4E-BP1 remained hyperphosphory-
lated in the presence of TMZ indicating that mTORC1
signalling was largely unaffected under these conditions,
even at 72 hours (Additional file 1: Figure S3). Protein syn-
thesis assays (Figure 1C; error bars are SE; n = 3) showed
that TMZ did not inhibit protein synthesis rates relative to
the untreated cells at 24 hours; indeed rates appeared to
be increased at 72 hours (p = 0.012).MGMT
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Figure 1 TMZ treatment does not affect steady state levels of MGMT
presence of TMZ for 24 hours (lane 2), 48 hours (lanes 3) or 72 hours (lane
indicated. B. MGMT protein levels in (A) were quantified and expressed rel
Confidence limits were set: *p = <0.2, **p = <0.05 ***p = <0.005. C. Cells we
Methods. Incorporation of radioactive methionine into protein was determ
incorporated in to cells incubated in the absence of TMZ. Error bars are theConcomitant TMZ treatment with KU0063794 causes an
increase in MGMT protein levels
To determine if combining mTOR inhibition with TMZ
chemotherapy effectively reduced MGMT protein le-
vels, we combined KU0063794 with TMZ and moni-
tored 4E-BP1 phosphorylation and MGMT protein levels
by SDS-PAGE and Western blotting, using alpha tubulin
as a protein loading control (Figure 2A). 4E-BP1 is de-
phosphorylated in cells treated with both KU0063794 and
TMZ, which is characteristic of mTORC1 inhibition. This
is consistent with the finding that concomitant treatment
of cells with both TMZ and KU0063794 resulted in the in-
hibition of p70S6K and increased phosphorylation of Akt
Thr308 (Additional file 1: Figure S4), both of which indi-
cate mTORC1 inhibition. Under these conditions, surpris-
ingly, when protein loading is taken into consideration
using alpha tubulin, levels of MGMT protein increased
(Figure 2A). Quantification of these data from three separ-
ate experiments (using alpha tubulin as a loading control;
error bars are SE) showed that although there was experi-
mental variability between time-courses, there was a sta-
tistically significant change in protein levels at 48 and
72 hours (p = 0.12 and 0.13, respectively) (Figure 2B).Time (Hours)
protein. T98G cells were incubated in the absence (lane 1) or
4). A. Proteins were visualised by Western blotting using the antiserum
ative to the eIF4A loading control. Error bars are the SE (n = 3).
re incubated with [35S] methionine, as described in Materials and
ined as cpm/μg protein; results are presented as a % of methionine
S.D (n = 3).
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Figure 2 TMZ combined with KU0063794 decreases MGMT protein levels compared to treatments with KU0063794 alone, but an
increase in overall MGMT protein levels is still observed. T98G cells were incubated in the absence (lane 1) or presence of TMZ and
KU0063794 for 12 hours (lane 2), 24 hours (lanes 3), 48 hours (lane 4) or 72 hours (lane 5). A Proteins were visualised by Western blotting using
the antiserum indicated. B. MGMT protein levels in (A) were quantified and expressed relative to the α tubulin loading control. Error bars are the
SE (n = 3). Confidence limits were set: *p = <0.2, **p = <0.05 ***p = <0.005. C. Cells were incubated in the absence or presence of KU0063794, TMZ
and KU0063794 or TMZ alone. Cells were incubated with [35S] methionine, as described in Materials and Methods. Incorporation of radioactive
methionine into protein was determined as cpm/μg protein; results are presented as a% of methionine incorporated in to cells incubated in the
absence of any treatments. Error bars are the S.D (n = 3).
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likely brought about by KU0063794 and overprinted the
lack of MGMT protein level change seen in the TMZ
treated cells alone (Figure 1). This was in spite of the fact
that protein synthesis rates were inhibited to the same
level with KU0063794 whether TMZ was present or not
(Figure 2C). Confocal microscopy was used to determine
the localisation of the MGMT protein within the cell
(Additional file 1: Figure S5), but, MGMT was not diffe-
rentially localised upon drug treatments, indicating that
the change in MGMT protein levels was not a reflection
of MGMT transport between cellular compartments.
KU0063794 treatment is responsible for the dramatic rise
in MGMT protein levels although global translation
remains reduced
Mutations in mTOR signalling pathways in GBM cells
can result in hyperactive PI3-K/mTOR signalling, pro-
moting cell survival, protein synthesis and cell prolifera-
tion [9,10,20]. KU0063794 directly inhibits this pathwayand should therefore prevent the cells from proliferating
and reduce their ability to synthesise new protein. To this
end, cells were treated with KU0063794 for 72 hours and
protein levels monitored by SDS-PAGE and immuno-
blotting. As expected, phosphorylation of 4E-BP1 on either
Ser65 or Thr70, and rpS6 on Ser240/244 were abrogated
within 12 hours of treatment of the cells with KU0063794
(Figure 3A lane 2 vs. lane 1), which indicates reduced trans-
lation initiation. At early time points, KU0063794 had little
effect on the phosphorylation of ERK1/2, p38MAPK or
eIF2α (Figure 3A, lanes 1–3), but phosphorylation was de-
creased at later time points (lanes 4 and 5). There was no
change in the total level of these proteins during the incu-
bation period (data not shown). In contrast, the phosphor-
ylation of Akt on Thr308 (an indicator of Akt activity)
increased with time (lanes 2–5 vs. lane 1) reflecting a previ-
ously reported feedback activation of PI3K and PDK1
following mTORC1 inhibition [13,14].
mTORC1, when active, regulates protein translation
through the phosphorylation of 4EBP1. Phosphorylation
Cdetaertn
U
sdae
B
4973600
U
K
eIF4A
p-eIF2α
p-4E-BP1 S65
0 72482412
Akt T308
p-p38 MAPK
p-p70 S6K T389
p-4E-BP1 T70
p-ERK 1/2 p42/44
eIF4G
eIF4A
p-eIF4E
4E-BP1
eIF4E
A B
p-S6 S240/44
Time (Hours)
1 5432
MGMT
α tubulin
4E-BP1
D
p21 cip1/waf1
Time (Hours)
0 72482412
E
Time (Hours)
Time (Hours)
%
 o
f c
on
tro
l
%
 c
ha
ng
e 
re
la
tiv
e 
to
 
α
 tu
bu
lin
 c
on
tro
l
1 5432
*
*
Figure 3 KU0063794 inhibits protein translation via mTOR kinase inhibition in T98G cells but MGMT protein levels are increased.
T98G cells were incubated in the absence (lane 1) or presence of KU0063794 for 12 hours (lane 2), 24 hours (lanes 3), 48 hours (lane 4) or 72 hours
(lane 5). A. Western blotting was carried out as described in Materials and Methods B. Aliquots of protein extract were subjected to m7GTP-Sepharose
affinity chromatography as described in Materials and Methods. Western blotting was carried out. All lanes were resolved on the same gel. C. T98G
cells were incubated in the absence (lane 1) or presence of KU0063794 for 12 hours (lane 2), 24 hours (lanes 3), 48 hours (lane 4) or 72 hours (lane 5).
Proteins were visualised by Western blotting using the antiserum indicated. D. MGMT protein levels in (C) were quantified and expressed relative to
the α tubulin loading control. Error bars are the SE (n = 3). Confidence limits were set: *p = <0.2, **p = <0.05 ***p = <0.005. E. Cells were incubated in
the absence or presence of KU0063794 as indicated. Mitochondrial activity (a measure of cell viability) was assessed using an MTS assay as described in
Materials and Methods and is expressed relative to untreated cells (set at 100%). Error bars are the S.D (n = 3).
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eIF4E to participate in the formation of the eIF4F com-
plex on the m7 GTP cap structure of mRNA and medi-
ate small ribosomal subunit binding and subsequent
protein translation [11]. As described above, cells were
incubated for 72 hours and the binding of eIF4E and
associated proteins with the 5’ end of mRNA was mea-
sured using Sepharose beads coupled with m7 GTP.
Bound protein was recovered and visualised using SDS-
PAGE and Western blotting alongside eIF4E and associ-
ated proteins isolated from untreated cells. As expected,
inhibition of mTORC1/2 signalling pathway resulted in
an increase in the binding of hypophosphorylated 4E-BP1 to recovered eIF4E and a moderate decrease in eIF4G
associated with eIF4E (Figure 3B). Unsurprisingly this ob-
servation was coupled with a reduction in protein synthe-
sis rates by around 70% upon treatment of KU0063794 for
48 hours (Figure 2C) and at 72 hours, the KU0063794
treated cells were synthesising protein at less than 10% of
the rate of the untreated control.
The levels of MGMT protein were also monitored in
cells treated with KU0063794, as this information was ne-
cessary to identify if the rise in MGMT levels during the
combined treatment of KU0063794 and TMZ was solely
caused by KU0063794 or if the effect observed was syner-
gistic. MGMT protein levels were not only maintained
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in a similar fashion to cells treated with both KU0063794
and TMZ, protein levels increased over a 72 hour period,
despite clear inhibition of mTORC1 (as shown by dephos-
phorylation of 4E-BP1, Figure 3C). Quantification of these
data from three separate experiments show that, relative
to the alpha tubulin protein loading control that MGMT
protein levels were increased by statistically significant
levels at 48 and 72 hours (p = 0.08 and 0.2, respectively) in
cells treated with KU0063794 alone compared with un-
treated controls (Figure 3D).
This observation clearly shows that the rise in MGMT
protein is caused by KU0063794. Yet it was not clear if the
rise in MGMT protein was protein specific or if mTORC1/
2 inhibition brought about a general inhibition of protein
degradation. To investigate this, we analysed the steady
state level of p21cip1, which is known to have a short half-
life (approximately 100 minutes [21]). The disappearance of
p21cip1 protein after 12 hours indicates that KU0063794
treatment does not cause a general inhibition of protein
degradation (Figure 3C), suggesting that the increase in
MGMT protein levels was indeed specific.
Cell viability (Figure 3E) and cell cycle progression in
T98G cells (Additional file 1: Figure S6) was also investi-
gated. KU0063794 had little effect on metabolic activity
(Figure 3E) but did cause a reduction in the S phase popu-
lation and a small increase in the sub-G1 population
(Additional file 1: Figure S6), indicative of an inhibition of
the cell cycle and some apoptosis at later incubation times.
To ensure that the effects observed during treatment
of all of the compounds were not cell specific, we also
used U87-MG cells. This glioma cell line expresses very
low levels of MGMT, which is confirmed by the absence
of MGMT protein when visualised by Western blotting
(Additional file 1: Figures S7, S8 and Additional file 2:
Figure S9). Both KU0063794 and TMZ generally had a
similar effect on the U87-MG cell line compared to the
T98G cell line. However, there were some differences in
responses observed here. The most obvious differences
were a less robust cessation of cell cycle progression in
U87-MG cells in response to KU0063794 and subtle diffe-
rences on mTORC1/2 and eIF2 alpha signalling pathways.
In U87-MG cells incubated with TMZ, there was no
change in 4E-BP1 or T308 phosphorylation but there was
an increase in eIF2 alpha phosphorylation, suggesting that
inhibition of translation under these conditions in U87-MG
cells may have been caused by eIF2 alpha phosphorylation.
mTOR1/2 inhibition results in selective translation of
MGMT during reduced protein synthesis rates
Considering that a combination of TMZ and KU0063794
did not, as expected, deplete the levels of MGMT protein
(although KU006374 treatment clearly causes a stark de-
phosphorylation of 4E-BP1 and a massive inhibition ofeIF4F complex formation), we hypothesised that the
MGMT mRNA may be post-transcriptionally regulated.
To investigate this further, polysome gradient analysis was
performed on cell extracts to monitor specific mRNAs as-
sociated with ribosomes and hence which are undergoing
active translation. As predicted, polysomes were disaggre-
gated in the presence of KU0063794, indicative of an in-
hibition of protein synthesis (Figure 4A). Using qRT-PCR,
we specifically investigated the translational profile of
MGMT mRNA across fractions from the sucrose density
gradients. In the absence of drug treatment both control
mRNA, GAPDH, and MGMT mRNA are preferentially
localised in the polysomes, especially the heavy polysomes,
and therefore reflect a high degree of translation (Figure 4B).
Treatment of cells with KU0063794 for 24 hours promoted
the relocation of a control mRNA, GAPDH, from heavy
polysomes to 80S monosomes (Figure 4C). This finding is
consistent with the observed inhibition of protein synthesis
(Figure 2C), as during reduced levels of protein synthesis
cap-dependant translation is generally inhibited, resulting
in a reduced amount of polysomes associated with mRNA.
Surprisingly, although global protein synthesis rates were
reduced, MGMT mRNA remained associated with heavy
polysomes when cells were incubated for 24 hours with
KU0063794 (Figure 4C). This could reflect maintenance of
translation of MGMT mRNA or else protection of this
mRNA in stalled polysomes; further work would be
required to elucidate this phenomenon.
We also confirmed that total mRNA expression did
not change on KU0063794 treatment using qRT-PCR
(Additional file 2: Figure S10). MGMT mRNA levels
remained unchanged at 24 hours compared to untreated cells
under all incubation conditions tested (relative to 18S rRNA).
Inhibition of mTOR signalling does not affect the half-life
of MGMT protein in T98G cells but stabilises MGMT
protein in the presence of TMZ
As inhibition of mTOR kinase activity is seen to inhibit glo-
bal protein synthesis rates yet increase the steady state level
of MGMT protein without affecting total mRNA levels, we
investigated whether this reflects a change in the half-life of
MGMT protein. To this end, cells were incubated in the
presence of emetine (alone) at a level to block protein syn-
thesis totally (Figure 5A, data not shown), or a combination
of emetine and KU0063794 (Figure 5B), TMZ (Figure 5C),
or KU0063794 and TMZ together (Figure 5D,E). MGMT
protein was relatively stable in T98G cells, with a half-life
of approximately 60 hours (Figure 5A). This did not change
when cells were incubated in the presence of KU0063794
(Figure 5B). However, the addition of TMZ reduced the
half-life of MGMT protein in T98G cells to less than
12 hours. This reflects the fact that MGMT undergoes pro-
teolysis after undergoing methylation as part of its DNA re-
pair function [6]; as emetine is entirely blocking protein
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http://www.molecular-cancer.com/content/13/1/144synthesis, MGMT is unable to be re-synthesised to main-
tain steady state levels (Figure 5C). Inhibition of mTOR sig-
nalling with KU0063794 concomitant with TMZ partially
restored steady state levels of MGMT (Figure 5D). These
data (quantified in Panel E from the representative Western
blots) suggest either that reduced mTOR activity promotes
MGMT stability or that KU0063794 interferes with the
proteasomal destruction of MGMT post-repair.
Discussion
GBM is the most aggressive adult brain cancer and
TMZ, an oral methylating chemotherapeutic agent, is
part of the standard treatment, often accompanied by
radiotherapy [2-4]. TMZ exerts its antitumour effect by
methylating guanine at a number of sites [22]. The N7
guanine and N3 adenine adducts caused by TMZ are
repaired by the base excision repair pathway, but the
O6-methyl-guanine (O6MeG) lesion cannot be repaired
in this fashion, making it the most potently cytotoxic ad-
duct [22]. O6MeG pairs with thymine and leads to GC-AT
transitions, beginning a cycle of futile DNA mismatchrepair which causes DNA double-stranded breaks and,
ultimately causes tumour cell death [6,22,23].
MGMT is a DNA repair protein that repairs the O6MeG
lesion created by TMZ by a process of irreversible binding
and subsequent degradation of the protein [5,23]. When
O6MeG is repaired by MGMT, the majority of cells become
resistant to O6MeG-triggered apoptosis [4-6]. Hence the
level of MGMTactivity correlates with resistance of tumour
cells to TMZ [24]. As mutations in the mTOR signalling
pathway in GBM frequently result in hyperactive PI3-K/
mTOR signalling, promoting cell survival and protein syn-
thesis [9,10,20], we investigated whether mTOR kinase ac-
tivity has a role in regulating levels of MGMT protein
expression in human glioblastoma cells.
As predicted, we show that TMZ does not reduce
MGMT protein levels in T98G cells, so the large
amount of MGMT in the cells is effectively repairing
any lesions created by TMZ. This suggests that, in
agreement with previous studies [25-27], on its own
TMZ is not sufficiently effective in cellular environ-
ments containing MGMT overexpression.
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Figure 5 Inhibition of mTOR signalling does not affect the half-life of MGMT protein in T98G cells but stabilises MGMT in the presence
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tein loading was accounted for in three separate experi-
ments, our data show that in cells treated with both
KU0063794 and TMZ, there was an increase in MGMT
protein expression. This occurred even though global pro-
tein synthesis rates were reduced by around 80% under
these conditions. These data suggest that although dual
mTOR inhibition was indeed impairing the formation of
the translation initiation complex, reducing global protein
synthesis rates and causing a disaggregation of polysomes
from mRNA, protein levels were still increasing. To de-
cipher if this unexpected maintenance of MGMT protein
levels was reliant on an alternative translation mechanism,
we assessed the translation status of MGMT mRNA. This
demonstrated that during conditions of reduced global
translation rates, and therefore reduced mRNA associationwith polysomes, MGMT mRNA remained associated with
heavy polysomes, although GAPDH mRNA shifted to sub
polysomal fractions. This is strong evidence that MGMT
mRNA might be translated using a cap-independent mech-
anism, or preferentially recruited to ribosomes under con-
ditions of low levels of eIF4F [28], but in the absence of
increased levels of eIF2α phosphorylation (Figure 3). This is
further supported by the presence of a number of GC-
rich short stem loops in the annotated 3’-UTR of the
MGMT mRNA, which may also have a role in this process.
Additional extensive biochemical analysis would be needed
to determine if this is the case. Alternative mechanisms
controlling translation have been identified under hyp-
oxic stress conditions, which rely on protein complexes
involving the alternative eIF4E isoform eIF4E2, specifi-
cally recruiting target mRNAs to polysomes during
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findings could compliment the preferential translation of
MGMT under stress conditions, but further investigations
would need to be carried out to confirm this.
In addition to the mechanisms regulating translational
control of MGMT mRNA, the stability of the MGMT pro-
tein was also investigated, as this is of paramount import-
ance when considering its manipulation for effective
chemotherapeutic treatment. The inhibition of protein syn-
thesis elongation with emetine in the presence of TMZ
caused a dramatic decrease in MGMT protein level, reflec-
ting the rapid degradation of the protein following DNA
repair activity (Figure 5). However, the combination of
KU0063794 and TMZ compared with TMZ alone resulted
in a lengthened half-life of MGMT protein to around
40 hours. This is an important observation, as an increase
in MGMT stability has the potential to greatly impede
treatment of GBM with DNA methylating agents.
Previous work has used the mTORC1 inhibitor rapamy-
cin to inhibit the mTOR/PI3K pathway in an attempt to in-
hibit the growth of GBM [30-32]. It was therefore a logical
progression to investigate specific mTOR signalling inhib-
ition in GBM cells and their possible use in conjunction
with TMZ. Even though research in this area is surprisingly
limited, recent studies have indicated combination treat-
ments involving compounds that negatively regulate the
mTOR signalling pathway may impact MGMT regulation
[33], further compounding the need for research to increase
the efficacy of TMZ. Indeed a number of clinical trials com-
bining mTOR inhibitors with radiation and TMZ have
been initiated and are recruiting patients (e.g. everolimus
(RTOG 0913) and BKM120).
The data presented here reveal that in vitro, rather than
inhibiting translation of MGMT, mTOR inhibition pro-
motes steady state levels of the MGMT protein and coun-
teracts the depleting effects of TMZ. We therefore conclude
that further in vivo analysis of mTOR inhibition is necessary
to determine if this effect is also found in patients exhibiting
GBM. If so, mTOR inhibition would not be a useful adjunct
to TMZ therapy in a clinical setting and could exacerbate
tumour growth.Additional files
Additional file 1: Figures S1 & S2. The effect of TMZ on cell cycle
progression in T98G cells. S1. T98G cells were incubated with drugs as
indicated for 24 hours and then harvested for FACS analysis. Error is S.D
(n = 3). S2. T98G cells were incubated as in S1. An MTS assay was
performed. Results are expressed relative to untreated cells. Error is S.D
(n = 3). Figure S3. TMZ does not affect mTORC1 signalling in T98G cells.
T98G cells were incubated as in S1 and proteins visualised by WB. Figure S4.
TMZ does not affect the inhibition of mTORC1 signalling by KU0063794
in T98G cells. T98G cells were incubated with drugs as indicated and
proteins visualised by WB. Figure S5. TMZ does not alter the
distribution of MGMT in T98G cells. T98G cells were incubated with
drugs as indicated. Cells were processed for IF visualisation of MGMT.The localisation of MGMT was quantified in the nuclear and cytoplasmic
regions. Figure S6. The effect of KU0063794 on cell cycle progression in
T98G cells. T98G cells were incubated as in S4 and harvested for FACS
analysis. Error is S.D (n = 3). Figure S7. The effect of KU0063794 and
TMZ on cell cycle progression in U87-MG cells. U87-MG cells were
incubated as in S5 and harvested for FACS analysis. Error is S.D (n = 3).
Figure S8 and S9. KU0063794 inhibits mTOR signalling and protein
synthesis in U87-MG cells. S8. U87-MG cells were incubated as in S7 and
proteins visualised by WB. S9. Incorporation of radioactive methionine
into cellular protein was measured. Error is S.D (n = 3). Figure S10. The
effect of KU0063794 on mRNA levels. T98G cells were incubated as in
S5 for 24 hours. Levels of MGMT mRNA is expressed as a fold change,
relative to levels in untreated cells.
Additional file 2: Figure S9. One hour prior to harvesting at 24 hours,
cells were incubated with [35S] methionine, as described in Materials and
Methods. Extracts were prepared and incorporation of radioactive
methionine into protein determined as cpm/μg protein; results are
presented as a % of the rate obtained in cells incubated in the absence
of TMZ incubated for 72 hours. Error bars are the S.D (n = 3). Figure S10.
The effect of KU0063794 on mRNA levels. T98G cells were incubated in the
absence or presence of 10 μM KU0063794, 10 μM TMZ or both 10 μM
KU0063794 and 10 μM TMZ for 24 hours and mRNA was extracted from cell
extracts as described in Materials and Methods. For each treatment,
quantitative RT-PCR was used to determine levels of MGMT mRNA relative
to 18rRNA, as described. Data are presented as a fold change in amount
relative to levels observed in untreated cells. Error bars are the S.D (n = 3).
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